Pfizer-Sanofi match not made in heaven?

Say the Pfizer/Sanofi-Aventis rumors are true: Would merging with the French drug maker boost Pfizer's fortunes? Not so much, say some observers.

The two companies do have some strengths in common--particularly their cardiovascular and central nervous system products. But they also share weaknesses. Some of their major patents would expire in tandem, for instance; Pfizer's blockbuster Lipitor goes off patent in 2012, and 2011 is D-Day for Sanofi-Aventis' Plavix (which it markets along with Bristol-Myers Squibb). So they also share a need for new big-selling products. And really--would the French easily relinquish one of their business jewels to American sway?

- read the Dow Jones column

Related Articles:
Sanofi stock up on Pfizer buyout talk. Report
Pfizer, Wyeth merger bad idea? Report

Read more on: Pfizer | Sanofi-Aventis

Suggested Articles

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing. 

Biocon’s key biosimilars plant in Bengaluru, India, has gotten mixed reviews from the FDA and has now received a Form 483 with five observations.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?